ESMO 2024 Conference Review – Breast Cancer Focus
In this review:
– CAPItello-290: capivasertib + paclitaxel in metastatic TNBC
– pCR & OS after neoadjuvant chemotherapy in stage I TNBC
– NATALEE: ribociclib + NSAI in younger patients with HR+/HER2− early breast cancer
– HERA: OFS in HR+/HER2+ breast cancer
– DESTINYBreast-12: T-DXd in HER2+ breast cancer ± brain metastases
– Capecitabine vs. IV chemotherapy for ER+/HER2- breast cancer after progression on endocrine treatment
– POSITIVE: breastfeeding after interruption of endocrine therapy for pregnancy
– Breastfeeding after breast cancer in BRCA carriers
– KEYNOTE-522: final OS results
– PROMENADE: KEYNOTE-522 regimen in ER-low/HER- breast cancer
– T-DXd-related ILD in HER2-driven breast cancer
Expert contributor
Dr David Okonji
MB BCh (UK) FRCP(Lon) MRCPS(Glas) FRACP David Okonji specialises in treating breast and urogenital cancers, as well as melanoma. He has a particular focus on cancer care in the elderly. David currently practises at Wellington Regional Hospital and also undertakes private practice at Bowen Hospital, Wellington. _ David is a Clinical Senior Lecturer at the […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
